ALVAC-CEA-B7.1
AXP000188.1 · Cancer vaccine
- Platform
- canarypox (ALVAC)
- Targets
- CEACAM5
Names
| Name | Type | Source |
|---|---|---|
| ALVAC-CEA-B7.1 | preferred name, code | curator, ncit |
| ALVAC-B7-CEA ambiguous | synonym | ncit |
| ALVAC-CEA (6D)-B7.1 ambiguous | synonym | ncit |
Virus
- Role
- Vaccine vector
- Family
- Poxviridae
- Virus
- canarypox virus (NCBI Taxonomy 44088)
- Strain
- ALVAC
- Replication
- non replicating
- Modifications
- CEA and CD80 (B7.1) cassettes in the ALVAC canarypox vector
- Transgenes
- CEACAM5, CD80
- Source
- evidence
Cross-references
- NCI Thesaurus
- C1977
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT00027833 | Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer | Unknown | Phase 2 | 2001-12 | Colorectal Cancer |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 18676757 | Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2008 | cited by trial NCT00027833 |
| PMID 11350882 | The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2001 | name in title: ALVAC-CEA-B7.1 |
| PMID 10873071 | Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2000 | name in abstract: ALVAC-CEA-B7.1 |
| PMID 11092617 | Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. | Cancer immunology, immunotherapy : CII | 2000 | name in abstract: ALVAC-CEA-B7.1 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 12596363 | Technology evaluation: ALVAC-CEA/B7.1, Aventis Pasteur/Therion. | Current opinion in molecular therapeutics | 2002 | name in title: ALVAC-CEA-B7.1 |
Notes
Replication-defective canarypox (ALVAC) vaccine encoding CEA (CEACAM5) with the costimulatory molecule B7.1 (CD80); early-phase NCI trials in CEA-expressing cancers, some with GM-CSF or chemotherapy. NCIt also holds a CEA(6D) epitope-modified variant (C29982) and plain ALVAC-CEA concepts (C1648, C2743); those are recorded as separate names here only where the construct matches. Originator (Virogenetics/Aventis Pasteur) and vCP code not verified in this pass.
How to cite
ALVAC-CEA-B7.1 (AXP000188.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000188.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.